New shot aims to silence hepatitis b virus for good

NCT ID NCT06425341

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 369 adults who are already on standard antiviral therapy will take part. The study is in Phase 2, meaning it is still early and focused on finding the right dose and checking safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanfang Hospital
RECRUITING

Guangzhou, Guangdong, 510515, China

Contact Phone: •••-•••-•••• Email: •••••@•••••